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BACKGROUND
To date, most efforts to understand the comparative population health impact of COVID-19 have
been made using mortality-based metrics [1,2]. This has intensified discussion over
methodological choices; in particular, how we value the life-years prematurely lost due to
COVID-19 [3]. So far, the direct impact of COVID-19 on population health has varied across
countries, with wide variation in incidence and infection fatality rates [4]. Understanding and
quantifying the combined impact of morbidity and mortality is a key step to standardizing
comparisons across countries, and to quantify the within-country impact of COVID-19 relative to
other causes of disease and injury, sub-national areas or demographics [5]. This can be achieved by
estimating summary measures of population health like disability-adjusted life years (DALYs). The
estimation of DALYs is useful to provide comprehensive and comparative public health
intelligence to inform decision-making for the management of the COVID-19 pandemic,
particularly around the extent of direct and indirect consequences [6]. At present, the Global
Burden of Disease (GBD) study has not integrated COVID-19. Some studies have already
estimated DALYs due to COVID-19. The first published assessment was performed for Korea,
up until the end of April 2020 [7]. An assessment, using a similar time frame, followed for Italy [8].
To date, published studies have only included one COVID-19 related health state, or disability
weights were country-specific [7–9].
AIM
Our paper provides a step-by-step guide to define COVID-19 as a cause of disease burden, which can be
used to calculate DALYs. Additionally, we suggest pragmatic data inputs, reflecting that availability and
quality of data inputs will vary by country. This paper builds on previous DALY calculation guides [10,11].
As our paper provides suggestions for different solutions, we recommend that users should be clear about
their methodological choices to aid comparisons and knowledge translation.
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METHODOLOGY
The impact of COVID-19 on health occurs through two main
pathways: directly, as an infectious disease; and indirectly, as a
risk factor, for example, through increases in mental health issues
due to national lockdowns or delays to surgery, follow-ups and
diagnoses through restrictions to vital healthcare services [6]. A
group within COST Action (European Cooperation in Science
and Technology) CA18218—European Burden of disease
Network—convened to establish a common methodological
approach to estimate DALYs directly due to COVID-19.
This paper presents the developed consensus approach in three
steps. The first relates to defining study parameters. The steps that
follow relate to estimating the impact of morbidity, in terms of years
lived with disability (YLD); and mortality, in terms of years lost to
premature mortality (YLL). DALYs quantify the full population
health impact and are calculated by summing YLD andYLL. DALYs
can be estimated based on grouped characteristics of interest, such as
demographics (e.g. age, sex, socioeconomic status, and ethnicity),
geographical region, or time.
Step 1: Defining Study Parameters
The first step in estimating DALYs is to define the space and time
for which the burden of disease assessment will take place. This
involves clear definitions of the population, which is being
studied, for example a country, or sub-national region of a
country. The time period is usually defined as a specific year
or grouped years. However as COVID-19 is a new disease, only
shorter time periods will initially be available.
Step 2: Morbidity—Estimating YLD
The second step in defining morbidity due to COVID-19 is to
establish the direct health states, which are experienced by
individuals infected by COVID-19 in an incidence-based model.
For each health state, there are three parameters, which require data
inputs: incidence; duration; and disability. YLD are calculated by
summing the product of the number of cases, duration (in years) and








Number of casesh × durationh × disability weighth,
with h  health state and l  number of health states. The COVID-
19 outcomes model is outlined in Figure 1, with detailed
information on health states, data input proxies and
corresponding disability weights outlined in Table 1. Health
state names, descriptions and disability weights are currently
based on those from the GBD 2019 study for infectious diseases of
the lower respiratory tract, with the exception of those requiring
FIGURE 1 |COVID-19 outcomes model and value of health loss. “DW” denotes disability weight; 95% uncertainty intervals for DW are displayed in brackets; “YLL”
denotes years of life lost due to premature mortality; “LE” denotes life expectancy; dashed line represents that individuals suffering from COVID-19may suffer permanent
impairments from other health states.
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intensive care, which was defined by the European Disability
Weight study [12–14]. As new evidence on type, severity and
duration of COVID-19 sequelae emerges, the outcome tree
should be updated accordingly.
Data inputs for YLD are largely dependent on the timeliness and
availability of estimates reported by individual countries, and are
sometimes based on COVID-19 transmission models. Our model
should therefore be adapted to suit individual circumstances, for
example, to reflect differences in restrictions and triaging across
hospitals, regions and countries, and how the state of the pandemic
increases service pressure, affecting the availability of healthcare
services. This recognizes the fact that the distribution of disease
occurrence across health states is likely to vary by location [15].
By definition, acute infection occurrence only contributes to YLD
if cases are symptomatic, however patients that are initially
asymptomatic may suffer YLD through post-acute consequences
(Figure 1). Although those that have sought healthcare support, or
testing, will vary between countries testing regimes and healthcare
capacity, identification of suspected/positive cases is the most widely
available proxy to use for symptomatic cases. There are potential
issues with the misclassification of asymptomatic cases that are tested,
due to difficulties capturing data on non-hospitalized symptomatic
cases. However, we cannot yet quantify the extent of this bias.
Corrective factors can be applied as, and when, this information
emerges. People who tested positive and/or notified cases represent
only a fraction of the true number of community cases (under-
ascertainment) as an unknown proportion do not seek healthcare,
and even among persons with severe or critical disease (hospitalized
or in intensive care) patient counts could be subject to underreporting.
As withmost other infectious diseases, for accurate estimation of YLD
due to COVID-19, adjustment of observed case counts for both
under-ascertainment and underreporting is fundamental. A number
of methods are available to adjust input data to estimate the true
incidence [16]. There is very little research to date on how this
estimation can be achieved for COVID-19. Data on healthcare-
seeking behavior and incidence estimates from transmission
models are two possible routes, if they are available for the
country/region in question. If only recorded case/patient counts
are used in the YLD calculation, then between-country
comparisons must recognize the inherent limitations due to
differences in surveillance systems, testing policy, and case
management. It is therefore important to capture the uncertainty
around estimates, particularly if referring to country comparisons.
Adjustment factors, such as positive tests as a proportion of total swab
tests could be used to adjust for variations in testing rates across
countries and over time to standardize comparisons. However, it is
important to establish the context of testing policies when making
comparisons as they may differ. For example, there may be locational
differences in testing policies, such as focusing testing on high-risk
settings, or as part of contact-tracing.
Assumptions over the mean duration in a health state can be
replaced by the calculation of person-years of infection when
daily data have been reported.When these cannot be calculated, it
is preferred to use estimates of the mean duration of 7.79 days
(95% uncertainty interval: 6.20–9.64 days) for lower respiratory
tract infections from the GBD study, or to derive them from
consultation with within-country clinical expert groups [17].
Additionally, if the granularity of data for community cases
permits, the YLD disease model can be refined to include mild
cases using a disability weight of 0.006 (95% uncertainty interval:
0.002–0.012) from the upper respiratory tract infections model.
There are several options to incorporate uncertainty in YLD
estimates. Credible intervals and/or lower and upper limits of
occurrence, duration, and disability weights can be used. These
can also include utilizing corrective factors, as evidence emerges,
regarding any issues with selection bias of input data. Additional
scenario analyses can also be undertaken to illustrate that other
plausible scenarios may have small effects on overall DALYs,
since YLD accumulates at a slower rate than YLL. At present,
there have been limited reports on the post-acute, and long-term
consequences of COVID-19 [18,19], but as more epidemiological
information on the occurrence and duration becomes available,
YLD can be refined to include these estimates using appropriate
transition probabilities.
Emerging evidence is showing that in some cases post-
acute consequences of COVID-19 (e.g. anosmia) may
significantly affect quality of life and that sometimes (e.g.
persistent symptoms) they may also lead to prolonged
healthcare utilization. It is however too early to assess the
full spectrum and burden of long-term sequelae associated
with COVID-19, so new knowledge on type, duration and
disability weight of COVID-19 sequelae will need to be
incorporated as more solid evidence becomes available.
Under a pathogen-based approach to estimating DALYs,
TABLE 1 | Example of health states and disability weights to consider for estimating the burden of COVID-19.









Has a fever and aches, and feels weak, which
causes some difficulty with daily activities






Has a high fever and pain, and feels very weak,
which causes great difficulty with daily activities
















Is always tired and easily upset. The person feels
pain all over the body and is depressed
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the long-term complications are attributed to the initial
infection to represent its natural history, provided there is
sufficient evidence for a causal relationship [20,21]. An
alternative is to assign any resultant new, or exacerbated,
non-communicable disease (NCD) within assessments of
cause-specific NCD burden. This is similar to the
approach that the GBD study use for causes of disease
such as cirrhosis, or liver cancer, caused be hepatitis C
infection [22].
Finally, we acknowledge that the COVID-19 crisis has led
to wider health effects that go beyond the morbidity linked to
the disease as such. For instance, lockdowns have led to an
insurgence of mental health problems, delayed health care-
seeking behavior and deferred follow-up of chronic
conditions may have increased the severity of common
chronic non-communicable diseases and their
complications. We however recommend to not include
these indirect effects in the COVID-19 disease model, and
to make an explicit distinction between COVID-19 as a
disease, and the COVID-19 crisis as a risk factor for ill-
health. As evidence emerges around the direct effects of
COVID-19 our disease model may warrant revisions.
Step 3: Mortality—Estimating YLL
When estimating YLL, two inputs are required: the number of
deaths; and conditional life expectancy, both of which must be








Number of deathsa × Remaining life expectancya,
where a  age-group, e.g. 1-year or 5-years group, n  number of
age-groups. Age-conditional life expectancy can be defined from
life tables (e.g. national, regional, or aspirational), and depends
on the age group. For internationally comparable results, which
may be important during a public health emergency of
international concern, the use of an aspirational life table
may be preferable [3].
Estimates of the number of deaths will largely depend on
data availability. Some countries may have timely mortality
data available by mutually exclusive causes of death, in which
case the underlying cause of death should be used. Depending
on the national death registration policy, some death
certificates may indicate ill-defined causes of death. If
possible, then redistribution can be considered to refine
estimates. Otherwise if deaths with COVID-19 as a
contributing cause can be determined, then a sensitivity
analysis using COVID-19 related (both COVID-19 cause-
specific and contributing) deaths may help gauge the
degree of potential underestimation of using cause-specific
deaths. Additionally, corrections can be considered to address
the potential underestimation of COVID-19 deaths, arising
due to death certification issues in the absence of laboratory
confirmed tests [23]. If death certification statistics are not
available, other alternatives exist. In countries where COVID-
19 is a notifiable disease, published mortality data on cases can
be used. However, care should be taken to ensure that these
data are unlikely to represent non-COVID-19 deaths, for
example by assessing the time-based inclusion criteria.
Alternatively, providing that non-COVID-19 mortality
rates are stable, estimates of the number of excess deaths
could be used as a proxy for COVID-19 deaths. An
uncertainty in using this approach is that these deaths will
also include a proportion due to indirect consequences of
COVID-19, for example those that occur as a consequence of
closures of vital services during national lockdowns. Another
option is to consider using transition probabilities from
published literature, which are useful for countries without
timely or reliable death registration information, taken from
existing case-fatality ratios. However, it may not be the case
that these are readily adaptable in different contexts, as the
management of patients may vary from one context to
another, and similarly the probability of dying given the
same disease severity.
CONCLUSION
The use of DALYs for estimating the burden of COVID-19
should be further explored in order to quantify the overall
impact of the pandemic going well beyond available COVID-
19 mortality figures. The use of burden of disease estimates can
inform policy makers about the actual magnitude of the overall
burden of the COVID-19 pandemic and may help trigger
action or better plan suitable mitigating measures.
A standard methodology for DALYs attributable to COVID-19
may allow more accurate and comparable estimates of the burden
of this disease. Uncertainties persist around COVID-19 data
quality and availability of information concerning sequelae from
COVID-19. Transparent reporting of uncertainties and limitations
is warranted to favor a correct interpretation of the results.
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